SG148190A1 - Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer - Google Patents

Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer

Info

Publication number
SG148190A1
SG148190A1 SG200808589-6A SG2008085896A SG148190A1 SG 148190 A1 SG148190 A1 SG 148190A1 SG 2008085896 A SG2008085896 A SG 2008085896A SG 148190 A1 SG148190 A1 SG 148190A1
Authority
SG
Singapore
Prior art keywords
treatment
cancer
diagnosis
angiogenesis inhibiting
inhibiting molecules
Prior art date
Application number
SG200808589-6A
Other languages
English (en)
Inventor
Beat A Imhof
Michel Aurrand-Lions
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/738,123 external-priority patent/US7642341B2/en
Application filed by Serono Lab filed Critical Serono Lab
Publication of SG148190A1 publication Critical patent/SG148190A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG200808589-6A 2003-11-19 2004-11-19 Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer SG148190A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03026629A EP1533617A1 (en) 2003-11-19 2003-11-19 Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
US10/738,123 US7642341B2 (en) 2003-12-18 2003-12-18 Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer

Publications (1)

Publication Number Publication Date
SG148190A1 true SG148190A1 (en) 2008-12-31

Family

ID=34621557

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200808589-6A SG148190A1 (en) 2003-11-19 2004-11-19 Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer

Country Status (19)

Country Link
US (1) US7790863B2 (ko)
EP (2) EP1533617A1 (ko)
JP (1) JP2007515159A (ko)
KR (1) KR101135834B1 (ko)
CN (1) CN1890567B (ko)
AT (1) ATE493657T1 (ko)
AU (1) AU2004291989B2 (ko)
BR (1) BRPI0415541B8 (ko)
CA (1) CA2546406C (ko)
DE (1) DE602004030819D1 (ko)
EA (1) EA009037B1 (ko)
ES (1) ES2358905T3 (ko)
HK (1) HK1097908A1 (ko)
IL (1) IL175686A (ko)
MX (1) MXPA06005523A (ko)
NO (1) NO20062793L (ko)
SG (1) SG148190A1 (ko)
WO (1) WO2005050213A1 (ko)
ZA (1) ZA200603069B (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1637019A (zh) 1999-03-11 2005-07-13 Rmf迪克塔吉恩有限公司 血管粘着分子及其功能的调节
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
JP2010504955A (ja) * 2006-09-28 2010-02-18 メルク セローノ ソシエテ アノニム 接合部接着分子ｃ（ｊａｍ−ｃ）結合化合物とその利用方法
EP2271774B1 (en) 2008-03-21 2018-03-07 MDxHealth Detection and prognosis of cervical cancer
CN102333875B (zh) 2009-02-27 2014-04-16 诺华股份有限公司 选择表达异源蛋白质的真核细胞的方法
WO2012104386A1 (en) 2011-02-02 2012-08-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonists of grasp55 for use as a medicament
WO2012160031A1 (en) * 2011-05-24 2012-11-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for prognosing solid tumor outcome
CA2888345C (en) 2012-10-24 2020-04-21 Research Development Foundation Jam-c antibodies and methods for treatment of cancer
GB201415367D0 (en) * 2014-08-29 2014-10-15 Iles Raymond K And Docherty Suzanne M E And Abban Thomas And Naase Mahmoud And Iles Jason K Methods for detecting abnormalities in haemoglobin
EP3277841A1 (en) * 2015-03-31 2018-02-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New biomarker for outcome in aml
RU2599545C1 (ru) * 2015-11-06 2016-10-10 государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный медико-стоматологический университет имени А.И. Евдокимова" Министерства здравоохранения Российской Федерации Способ подавления роста опухоли основе in vitro репрограммирования макрофагов на м1 фенотип с повышенной способностью к продукции оксида азота в эксперименте

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) * 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) * 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
ATE352613T1 (de) 1995-08-29 2007-02-15 Kirin Brewery Chimäres tier und methode zu dessen herstellung
JP4318752B2 (ja) * 1996-05-31 2009-08-26 ヘルス・リサーチ・インコーポレーテッド 抗エンドグリンモノクローナル抗体および抗血管新生治療におけるその使用
CN1637019A (zh) * 1999-03-11 2005-07-13 Rmf迪克塔吉恩有限公司 血管粘着分子及其功能的调节
EP1792991A1 (en) 1999-08-24 2007-06-06 Medarex, Inc. Human CTLA-4 antibodies and their uses
CA2634294A1 (en) * 2000-08-03 2002-02-14 Therapeutic Human Polyclonals, Inc. Production of humanized antibodies in transgenic animals
US7041870B2 (en) 2000-11-30 2006-05-09 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
WO2003006673A2 (en) * 2001-07-11 2003-01-23 Texas Biotechnology Corporation A nucleic acid encoding a human junctional adhesion protein (jam3)
WO2003008541A2 (en) * 2001-07-16 2003-01-30 Eli Lilly And Company Extracellular junctional adhesion molecules
US20030035802A1 (en) * 2001-08-14 2003-02-20 Dewan Zeng Localization of A2B AdoR on human normal and diseased tissue: the use of anti-A2B antibody to diagnose and treat human tumors
CA2471702C (en) 2002-01-09 2013-03-19 Medarex, Inc. Human monoclonal antibodies against cd30
JP4739763B2 (ja) * 2002-12-16 2011-08-03 ゲンマブ エー／エス インターロイキン８（ｉｌ−８）に対するヒトモノクローナル抗体
WO2004055056A1 (en) 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
US7642341B2 (en) * 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer

Also Published As

Publication number Publication date
EA009037B1 (ru) 2007-10-26
CN1890567B (zh) 2012-12-12
ZA200603069B (en) 2007-09-26
IL175686A (en) 2012-02-29
US7790863B2 (en) 2010-09-07
KR101135834B1 (ko) 2012-04-16
WO2005050213A1 (en) 2005-06-02
MXPA06005523A (es) 2006-12-14
EP1533617A1 (en) 2005-05-25
CN1890567A (zh) 2007-01-03
AU2004291989B2 (en) 2009-08-06
EP1685405A1 (en) 2006-08-02
ES2358905T3 (es) 2011-05-16
EP1685405B1 (en) 2010-12-29
HK1097908A1 (en) 2007-07-06
JP2007515159A (ja) 2007-06-14
IL175686A0 (en) 2006-09-05
BRPI0415541B1 (pt) 2018-11-27
EA200600995A1 (ru) 2006-10-27
NO20062793L (no) 2006-08-18
US20070202110A1 (en) 2007-08-30
BRPI0415541B8 (pt) 2021-05-25
BRPI0415541A (pt) 2006-12-26
AU2004291989A1 (en) 2005-06-02
CA2546406C (en) 2013-04-09
DE602004030819D1 (de) 2011-02-10
CA2546406A1 (en) 2005-06-02
KR20060130562A (ko) 2006-12-19
ATE493657T1 (de) 2011-01-15

Similar Documents

Publication Publication Date Title
CY1118369T1 (el) Αντισωματα εναντι cd38 για την θεραπεια πολλαπλου μυελωματος
GEP20084476B (en) Recombinant antibodies and fragments recognising ganglioside n-glycolyl-gm3 and use thereof in the diagnosis and treatment of tumours
DE60028970D1 (de) An her2 bindende peptidverbindungen
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
UA90082C2 (ru) Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25
WO2005103081A3 (en) Human monoclonal antibodies against cd20
WO2006089141A3 (en) Antibodies against cxcr4 and methods of use thereof
EP1470146B8 (en) Antibodies against the muc18 antigen
MY194997A (en) Anti-ccr7 antibody drug conjugates
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
EP1467757A4 (en) USE OF ANTIBODIES TO THE MUC18 ANTIGEN
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
GEP20135826B (en) Novel antibodies used to treat cancer
WO2021227307A8 (zh) 抗cd73抗体及其用途
WO2005028498A3 (en) Kid3 and kid3 antibodies that bind thereto
WO2004060304A3 (en) Novel compositions and methods in cancer
SG148190A1 (en) Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer
MX2021011715A (es) Anticuerpos contra amiloide-? con piroglutamato y usos de estos campo de la invención.
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
MX2023001776A (es) Anticuerpos contra ilt2 y uso de los mismos.
WO2003080808A3 (en) Novel compositions and methods in cancer
WO2021067633A3 (en) Kir3dl3 is an inhibitory receptor of the immune system and uses thereof
MX2021008453A (es) Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos.
WO2008042941A3 (en) Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease
WO2005010153A3 (en) Antibodies and uses thereof